▌参考文献: [1] Jie Zhang, Chunfang Hao. YO7 - Sacituzumab Govitecan in the Treatment of Recurrent Triple-Negative Breast Cancer in a Patient with HRD-Positive and BRCA1/2 Wild-Type Germline: A Case Report. 2024 ...
▌参考文献: [1] Jie Zhang, Chunfang Hao. YO7 - Sacituzumab Govitecan in the Treatment of Recurrent Triple-Negative Breast Cancer in a Patient with HRD-Positive and BRCA1/2 Wild-Type Germline: A Case Report. 2024 ESMO Asia YO-7. [2] Bardia A, Hurvitz SA, Tolaney SM, et al. Sac...
Both cohorts included mutations ingBRIP1(1),gPALB2(1),gRAD51C(3),sBRCA1(2), with 1 COSMIC mutational signature 3, and 1 positive HRD score in HGSOC. OTRR at 6m was 40% in HGSOC (6/15: 5 partial, 1 complete), and 0% in TNBC (0/7). OTRR was 38% (3/8) in methylated...
Thus, we set the LOD of HRD-positive status as tumor purity 20% (Supplementary Figure 2. A). Two clinical samples with different HRD scores were repeated for the cancer panel assay. In addition, the average coefficient of variation (CV) of the two samples was 2.44%. For the sample set...
Myriad HRD assay VS HRR assay • 44% HRD positive ,其中57% HRRm HRD genomic scar可以identify所有BRCA甲基化患者; HRD患者只有近一半可通过HRRm gene panel检测出来 Melinda S. Yates, PhD, 2017 ASCO FMI HRD assay VS HRR assay 不同研究显示,HRD Scar检测的阳性患者高于HRRm gene panel检测的 阳性...
BRCA LOH Assay检测流程 及结果判读 ASCO 2018 Abstract 5545. LOH状态BRCA结果 Foundation Focus结果 高阴性阳性 高阳性阳性 低阳性阳性 低阴性阴性 肿瘤样本中LOH 的片段占整个基因组的比例, 16%为LOH高 基因LOH状态 FoundationFocus CDx BRCA LOH Assay结果 Myriad HRD assay VS HRR assay 44% HRD positive, ...
The approach significantly reduced the time and cost associated with identifying actionable genomic biomarkers, thereby accelerating the initiation of targeted therapies for patients with HRD-positive breast and ovarian cancers The study emphasizes the potential of this AI-driven method to address health di...
The first wasn't really all that surprising. It's that women who harbor a germline mutation in BRCA1 or BRCA2 or have a somatic BRCA tumor mutation or HRD-positive disease have an improved progression-free survival and overall survival, regardless of whether they received primary...
The proportion of patients with positive HRD status was 64.4%. Such results reveal that, compared to Western population, a higher proportion of Chinese ovarian cancer patients benefit from PARP inhibitor maintenance therapy. HRR gene mutation and HRD status are highly correlated with platinum chemothera...
Single-agent olaparib (Lynparza) and niraparib (Zejula) have shown a significant extension in progression-free survival (PFS) as frontline maintenance therapy in patients with homologous recombination deficient (HRD)–positive ovarian cancer, explained Hye Sook Chon, MD, who added that although the...